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Abstract
Background: Unexplained fatigue is often left untreated or treated with antidepressants. This randomized, placebo-
controlled, single-blinded study evaluated the efficacy and tolerability of single-dose intravenous ferric carboxymaltose
(FCM) in iron-deficient, premenopausal women with symptomatic, unexplained fatigue.
Methods: Fatigued women (Piper Fatigue Scale [PFS] score $5) with iron deficiency (ferritin ,50 mg/L and transferrin
saturation,20%, or ferritin,15 mg/L) and normal or borderline hemoglobin ($115 g/L) were enrolled in 21 sites in Austria,
Germany, Sweden and Switzerland, blinded to the study drug and randomized (computer-generated randomization
sequence) to a single FCM (1000 mg iron) or saline (placebo) infusion. Primary endpoint was the proportion of patients with
reduced fatigue ($1 point decrease in PFS score from baseline to Day 56).
Results: The full analysis included 290 women (FCM 144, placebo 146). Fatigue was reduced in 65.3% (FCM) and 52.7%
(placebo) of patients (OR 1.68, 95%CI 1.05–2.70; p = 0.03). A 50% reduction of PFS score was achieved in 33.3% FCM- vs.
16.4% placebo-treated patients (p,0.001). At Day 56, all FCM-treated patients had hemoglobin levels $120 g/L (vs. 87% at
baseline); with placebo, the proportion decreased from 86% to 81%. Mental quality-of-life (SF-12) and the cognitive function
scores improved better with FCM. ‘Power of attention’ improved better in FCM-treated patients with ferritin ,15 mg/L.
Treatment-emergent adverse events (placebo 114, FCM 209; most frequently headache, nasopharyngitis, pyrexia and
nausea) were mainly mild or moderate.
Conclusion: A single infusion of FCM improved fatigue, mental quality-of-life, cognitive function and erythropoiesis in iron-
deficient women with normal or borderline hemoglobin. Although more side effects were reported compared to placebo,
FCM can be an effective alternative in patients who cannot tolerate or use oral iron, the common treatment of iron
deficiency. Overall, the results support the hypothesis that iron deficiency can affect women’s health, and a normal iron
status should be maintained independent of hemoglobin levels.
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Introduction
Fatigue is a major health problem, affecting 14–32% of patients
in primary care, particularly women [1–3], and often left
untreated or subject to antidepressant therapy. Similar to reduced
physical performance and cognitive function, fatigue is closely
associated with anemia and iron deficiency (ID) [4–8] which are
leading causes of disability as indicated by the global burden of
disease study [9]. Since iron is not only a component of
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hemoglobin (Hb) but also a key element of various essential
enzymes in all metabolic pathways (e.g. oxidative phosphorylation)
[10], ID can have an Hb-independent effect on physical
performance and fatigue [4],[11],[12].
A slow onset of ID-associated symptoms may lead patients to
adapt to fatigue and consequently, they may not request medical
help. Therefore, ID may be broadly unrecognized despite being
one of the most prevalent nutrient deficiencies affecting human
health and accounting for most anemia cases in underprivileged
populations[13]. Even in industrialized countries a prevalence rate
of 4–33% is reported, with ID being particularly common e.g. in
menstruating women [14],[15].
Although previous randomized clinical trials have indicated that
iron treatment (long-term oral or repeated intravenous [i.v.] iron)
can reduce fatigue in iron-deficient, non-anemic (IDNA) women
[5],[7],[8], the true benefit of iron supplementation in these
patients is still controversial. This larger study, PREFER,
evaluated the efficacy and tolerability of a single infusion of ferric
carboxymaltose (FCM) in improving fatigue symptoms, quality-of-
life (QoL), and cognitive function in iron-deficient, premenopausal
women without active or chronic medical conditions (to exclude
the mainly inflammation-related chronic fatigue syndrome).
Compared to previous studies, fatigue symptoms were compre-
hensively assessed using the validated 22-item Piper Fatigue Scale
(PFS) [16] and computerized cognitive functions test systems that
are highly sensitivity for impairment or enhancement.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Design and Setting
This study was designed as a randomized, placebo-controlled,
single-blinded, comparative superiority study. The study was
conducted from November 2010 to November 2011 at 21 sites,
including private practices and general hospitals in Austria,
Germany, Sweden, and Switzerland.
It was performed in compliance with the Declaration of Helsinki
and the Guideline of Good Clinical Practice, registered at
ClinicalTrials.gov (NCT01110356) and approved by independent
ethics committees (GERMANY: Ethik-Kommission des Landes
Sachsen-Anhalt (Lead EC), Ethik-Kommission der A¨rztekammer
Niedersachsen, Ethikkommission zur Beratung anderer beruf-
sethischer Fragen, A¨rztekammer Nordrhein - Ethik-Kommission,
Ethik-Kommission der A¨rztekammer Hamburg, Ethikkommission
an der Medizinischen Fakulta¨t der Universita¨t Rostock, Ethik-
Kommission Landesamt fu¨r Gesundheit und Soziales (LaGeSo),
Ethik-Kommission der A¨rztekammer Schleswig-Holstein; AUS-
TRIA: Ethik-Kommission der Medizinischen Universita¨t Wien
und des Allgemeinen Krankenhauses der Stadt Wien - AKH (Lead
EC), Ethik-Kommission der Confraternita¨t & Privatklinik Do¨-
bling; SWEDEN: Regional Ethics Review Board in Uppsala (Lead
EC); SWITZERLAND: Commission Cantonale (VD) d’Ethique,
Kantonale Ethikkommission Aarau, Kantonale Ethikkommission
Zu¨rich, Ethikkommission des Kantons St. Gallen, Kantonale
Ethikkommission Bern). All patients gave written informed
consent prior to study-related procedures.
Study Population
Eligible patients were premenopausal, regularly menstruating
women $18 years of age with symptomatic fatigue ($5 points on
the PFS) [16], who had ID with an unknown etiology (e.g., no
menorrhagia) but had normal or borderline hemoglobin (Hb $
115 g/L) at screening. Based on recommendations in other
indications [17–20] and similar to the FERRIM study [5], ID
was defined as serum ferritin ,50 mg/L and transferrin saturation
(TSAT) ,20%, or ferritin ,15 mg/L. Further inclusion criteria
were a body weight of 50–90 kg (to exclude potential overweight-
related impairment of iron metabolism), a negative pregnancy test
and normal levels of C-reactive protein, thyroid-stimulating
hormone, vitamin B12 and folic acid (according to each centers
protocol).
Patients were excluded if they had any active or unstable
concurrent medical condition, any major depressive disorder,
ongoing infections or chronic inflammatory disease, any history of
sleep apnea or concurrent medications that could affect physical or
mental performance, a known sensitivity to any iron preparation,
or use of iron preparations within 4 weeks prior screening.
Randomization and Intervention
Baseline assessment and 1:1 randomization to a single infusion
of either FCM or placebo (Day 0) were performed within 14 days
of the screening visit (patient flow in fig. 1). Treatment allocation
followed a computer-generated list of random numbers that has
been prepared by the clinical research organization using block
randomization with variable block length (2, 4). No stratification
was considered. Investigators received a set of sealed envelopes
that corresponded to a randomization number and contained the
identity of the study drug, and prepared and administered the
study drug. Patients were blinded to the study treatment by
covering infusion bags with opaque bags and using dark-colored
infusion lines.
FCM (1000 mg iron) was diluted in 250 mL sterile 0.9%
sodium chloride solution and administered as a single infusion
over at least 15 min without the requirement for a test dose.
Placebo-treated patients received 250 mL saline solution under
identical conditions.
Outcomes and Follow-up
Hematology and iron status (serum ferritin, TSAT), soluble
transferrin receptor [sTfR]), were evaluated at baseline (pre-dose)
and follow-up visits (Days 7, 28 and 56 or early termination visit).
Blood biochemistry, including serum phosphate levels, was
assessed at baseline, Day 7 and Day 56. Fatigue symptoms and
treatment efficacy were assessed by the 22-item PFS [16] at each
visit (classification of severity: 1–3 none or mild, 4–6 moderate, 7–
10 severe). Additional efficacy measures were the SF-12 QoL
questionnaire [21] (baseline and Day 56), and computerized
cognitive tests, performed at each visit with the CDR system [22]
(assessing attention, concentration and short-term memory) and
the Bond-Lader visual analogue scale (VAS) (self-rated assessment
of alertness, contentment and calmness) [23].
The primary endpoint was defined as the proportion of patients
who achieved a$1 point decrease in total PFS score from baseline
to Day 56. Secondary endpoints included mean changes from
baseline to Day 56 in PFS total and subscale scores, the SF-
12 QoL questionnaire [21] and cognitive function tests. Further-
more, the proportion of patients with Hb $120 g/L, ferritin $
50 mg/L and TSAT $20% at Day 56 as well as the relationship
between the change in ferritin and the success rate in cognitive
tests were assessed. An additional objective that was defined before
analysis of the data was the proportion of patients with 50% PFS-
reduction.
Safety endpoints, including frequency of adverse events (AEs)
and abnormal laboratory parameters, were evaluated at each visit.
AEs that began or worsened in severity after study drug
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administration were considered treatment-emergent (TEAEs).
Intensity/severity of an AE was categorized as ‘mild’, ‘moderate’
or ‘severe’ by the investigators. Events were categorized ‘related’
or ‘unrelated’ to the study drug (binary scale).
Statistical Analysis
Sample size estimation (288 patients; 144 per group) was based
on a two-group x2 test with a 0.050 two-sided significance level,
80% power, a 10% drop-out rate, and a 17% minimum difference
of responders between groups (calculated from response rates
observed in a related subgroup in the FERRIM trial [5]).
The analysis populations comprised the safety set (SAF; all
randomized patients who had received study treatment), the intent
to treat set (ITT; treated patients with available post-baseline
efficacy data) and the per-protocol set (PP; patients with available
values of the relevant study variables at all periods and no major
protocol violation).
Descriptive statistics of continuous data comprised mean6SD
(standard deviation), median with interquartile range, and
between-group difference with 95%CI (confidence interval). The
primary objective was analyzed via two-sided x2-test (alpha-level:
0.05). Changes in outcome measures were analyzed by mixed
model repeated ANOVA (PROC MIXED in SAS). SF-12 was
analyzed using a t-test. Single missing data were imputed using the
last observation carried forward rule. Derived variables were
calculated afterwards.
Results
Patient Characteristics
Of 861 screened patients, 294 fulfilled the inclusion-criteria and
were randomized and treated (SAF: 145 to FCM, 149 to placebo).
Of those, 290 patients were included in the ITT (FCM: 144;
placebo: 146; fig. 1). The mean age was 35 years. Baseline clinical
and laboratory characteristics were similar for the two treatment
groups (table 1). Hb levels ,120 g/L were measured in 19
[13.1%] patients of the FCM and 21 [14.1%] of the placebo
group. Most enrolled patients (283 [96.3%]) completed the trial
(FCM: 142 [97.9%]; placebo: 141 [94.6%]). Eleven patients
withdrew prematurely, with ‘‘lost to follow-up’’ (FCM: 2 patients;
placebo: 4 patients) being the most common reason. Two placebo-
treated patients discontinued due to lack of efficacy.
Fatigue Improvement
The percentage of patients with improved total PFS score ($1
point decrease from baseline to Day 56) was statistically
Figure 1. Study flow diagram. The most common major protocol deviations were ‘disallowed concurrent medications’ (15 patients in the placebo
and 19 patients in the FCM group) and ‘selection criteria not met’ (5 patients in the placebo and 8 patients in the FCM group).
doi:10.1371/journal.pone.0094217.g001
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significantly higher in the FCM arm (65.3%) than in the placebo
arm (52.7%) (difference: 12.5% [1.3% to 23.8%]; number needed
to treat [NNT]= 8.0; P = 0.03; ITT; table 2, fig. 2A). A 50%-
reduction of PFS total score at Day 56 was achieved by 33.3%
FCM- vs. 16.4% placebo-treated patients (difference: 16.9%
[7.1% to 26.7%]; NNT=5.9; P,0.001). The latter treatment
effect was also significant in the subpopulation of patients with
baseline Hb $120 g/L (FCM: 29.6%; placebo: 16.8%; difference
12.8%; NNT=7.7; P = 0.016). A lower mean total PFS score in
the FCM vs. the placebo group was already observed after one
week (fig. 2B). At Day 56, improvement in all PFS subscores was
significantly greater in FCM-treated patients (table 3, fig. 2C). In
the PP, the results were even more in favor of the FCM group
(primary endpoint: difference 14.3% [2.5% to 26.2%], P= 0.019).
Mental and Physical Quality-of-life
Mean improvement in the SF-12 mental health summary from
baseline to Day 56 was better in the FCM group compared to
placebo (P= 0.007; table 3). Improvement in physical health was
numerically, but not statistically significantly, better in FCM-
treated patients (table 3).
Cognitive Function
A mixed model analysis of changes in VAS scores showed that
FCM treatment led to significantly better improvement in
alertness compared to placebo from Day 7 onwards (difference:
4.30 [0.73 to 7.88]; P= 0.019). At Day 56, FCM-associated
improvement was significantly better for contentment and showed
a trend for calmness (table 3, fig. 2D).
Changes in cognitive function subscales were numerically larger
with FCM but not significantly different to placebo. Among
patients with ferritin ,15 mg/L, an FCM-associated significantly
better improvement in ‘power of attention’ was seen at Day 56
(difference FCM vs. placebo: 238.4 msec [265.8 to 211.0];
P = 0.006).
Hematologic Response and Iron Status
At Day 56, all FCM-treated patients achieved Hb levels $
120 g/L (mean [min, max] 134 g/L [120, 159]) whereas 19.2% of
placebo-treated patients had lower Hb levels (127 g/L [89, 154];
P,0.001; table 4). Mean reticulocyte count increased transiently
in FCM-treated patients at Days 7–28 followed by an increase in
Hb and mean corpuscular volume (MCV) from Day 28 onwards
(fig. 3A–C). The majority of FCM-treated patients achieved
normal iron status (ferritin, TSAT) at Day 56, whereas most
placebo-treated patients had subnormal iron indices (table 4,
fig. 3D). Mean levels of sTfR were significantly lower in FCM vs.
placebo-treated patients at all time-points (Day 7: 20.3260.32 vs.
0.0260.27 mg/L; Day 28: 20.3760.42 vs. 0.0760.42 mg/L;
Day 56: 20.5660.51 vs. 0.1360.61 mg/L; all time-points P,
0.001). Among FCM-treated patients, the extent of changes in
ferritin did not correlate with changes in other endpoints. An
additional analysis including the patients of both groups (FCM and
placebo) confirmed that the increase in ferritin correlated with
improvement in the fatigue score (Spearman correlation coeffi-
cient, r =20.173; P = 0.003).
Tolerability and Biochemical Analyses
TEAEs were experienced by 57.2% of FCM- and 49.0% of
placebo-treated patients (P = 0.16, not significant at alpha= 0.05
level; table 5). The most frequently reported TEAEs were
headache, nasopharyngitis, pyrexia and nausea. Overall, TEAS
were mainly mild (66.5% vs. 63.2%) or moderate (28.2% vs.
36.8%) in intensity. The frequency of infections and infection-like
symptoms was similar in the FCM and placebo group (18.6% vs.
20.1%: P=0.74). Among 66 events of infections and infestations in
57 (19.4%) patients, nasopharyngitis (21 in 21 patients), respiratory
tract infections (6 in 6 patients) and sinusitis (5 in 5 patients)
occurred most frequently and without significant difference
between the treatment groups. The TEAEs by system organ class
that were reported more frequently in the FCM group were
general disorders and administration site conditions (16.6% vs.
2.7%; P,0.05), nervous system disorders (20.0% vs. 12.1%;
P= 0.06) and gastrointestinal disorders (11.7% vs. 6.0%; P= 0.09).
Five FCM-treated patients reported severe TEAEs; in four, the
events were considered drug-related (one patient: nausea, head-
ache, heavy legs, arthralgia, myalgia; one patient: hematoma and
2x discoloration at injection sites; one patient: headache; one
patient: nightly sweat). An additional covariate analysis indicated
that relatively young age and low body weight were independent
risk factors for all and related TEAEs, with age being the more
relevant factor. Patients younger than 34 years (study population’s
median age, n= 69) experienced more often at least one TEAE or
related TEAE than patients that were older (n = 76) (68.8% vs.
51.3%; P,0.0001 or 37.7% vs. 19.7%; P,0.0001, respectively).
Among patients with a body weight #65 kg (n = 79) and a weight
Table 1. Patient baseline characteristics, SAF.
Mean (SD), median (Q1, Q3)* FCM (N=145) Placebo (N=149)
Age [years] 34.6 (8.8) 35.0 (9.6)
Weight [kg]* 64.0 (57.0, 72.5) 63.0 (58.4, 75.4)
PFS* 6.4 (5.7, 7.2) 6.4 (5.5, 7.3)
SF12 (Mental Score) 41.2 (9.7) 42.3 (9.2)
SF12 (Physical Score) 44.5 (8.2) 43.8 (8.1)
Hb [g/L]* 128 (124, 135) 129 (122, 134)
MCV [fL]* 87.4 (84.1, 90.0) 87.0 (85.0, 91.0)
Serum ferritin [mg/L]* 15 (10, 25) 16 (11, 28)
TSAT [%]* 14.0 (10.0, 18.0) 14.4 (10.9, 18.5)
CRP [mg/L]* 2.0 (1.0, 3.1) 1.7 (1.0, 3.1)
*Weight, PFS, Hb, MCV, serum ferritin, TSAT and CRP shown as median (Q1, Q3).
CRP C-reactive protein; Hb hemoglobin; MCV mean corpuscular volume; PFS piper fatigue scale; TSAT transferrin saturation.
doi:10.1371/journal.pone.0094217.t001
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.65 kg (n= 66), similar proportions had at least one TEAE
(55.7% vs. 59.1%) but more patients with a body weight #65 kg
had a related TEAE (36.7% vs. 18.2%).
No drug-related severe or serious allergic reactions were
observed. One moderate hypersensitivity reaction after FCM
infusion that resolved on the same day was reported in a patient
with a history of hypersensitivity.
Most FCM-treated patients had a clinically asymptomatic,
transient decrease in serum phosphate below normal (0.8 mmol/
L) at Day 7 (86% [FCM] vs. 2% [placebo]; 0.6260.41 vs.
1.1260.18 mmol/L) that resolved spontaneously until end-of-
Figure 2. Treatment effects of FCM vs. placebo in fatigued, iron-deficient, non-anemic women (ITT; error bars SD). (A) Proportion of
patients with $1 point reduction in PFS (primary endpoint). (B) Improvement of mean PFS total score in FCM- vs. placebo-treated patients
throughout the study (Mean differences 6 SD vs. baseline: Day 7: 21.261.8 vs. 20.861.5 points; Day 28: 21.862.1 vs. 1.262.0 points; Day 56:
22.262.1 vs.21.462.0 points). P-values given for intergroup differences. (C) Mean change (D) in PFS total score and subscale scores from baseline to
Day 56. *P#0.01 for all scales. (D) Mean change (D) in self-rated alertness, contentment and calmness (computer-based VAS scales). *P,0.05;
{P= 0.055 vs. placebo.
doi:10.1371/journal.pone.0094217.g002
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study in almost all FCM-treated patients (91.9%; 1.0960.24 vs.
1.1760.30 mmol/L [FCM vs. placebo]). No other clinically
meaningful between-group differences in laboratory parameters
were observed. One treatment-unrelated serious AE has been
reported in the FCM group (moderate left thoracic pain). No
deaths or AE-related premature discontinuation of the study drug
were reported.
Discussion
So far, there was only limited clinical evidence that ID without
anemia may cause chronic fatigue and impair QoL in menstru-
ating women that appear to be healthy [5],[7],[8]. This study,
PREFER, demonstrates that iron repletion with a single FCM-
infusion (1000 mg iron) effectively and quickly reduced fatigue
symptoms, and improved patient-rated mental QoL, cognitive
functions and erythropoiesis in iron-deficient women with normal
or borderline hemoglobin levels.
Three randomized controlled studies have reported that long-
term oral iron can improve fatigue in IDNA women [7],[8],[24].
However, oral iron has limitations such as long time to response
(particularly in case of recurrent blood loss as in menstruating
women), gastrointestinal side effects, low adherence to therapy,
and lack of QoL improvement [8],[25]. Notably, constipation and
blackened stool may have compromised patient blinding in two
studies [7],[8] resulting in higher reported response rates in the
treatment group and lower placebo-effects. One randomized,
controlled pilot study on repeated i.v. iron sucrose administration
in IDNA women showed a trend that 46200 mg iron over two
weeks may reduce fatigue [5]. While the study’s primary endpoint
(decrease in fatigue 6 weeks after treatment initiation) did not
reach statistical significance vs. placebo, post-hoc analyses
demonstrated a significant effect on fatigue.
In our study the 22-item PFS [16], the SF-12 health-related
short form and cognitive function tests were used to evaluate and
monitor patients’ fatigue and overall condition. Currently, no
target levels or improvements are defined for fatigue. However,
improvement of fatigue by a $1 point decrease in PFS score
(primary endpoint) is considered clinically relevant [26] and
corresponds to a $10% improvement on this scale, which is
similar to the previously reported 0.97 point mean decrease on a
10-point VAS [7]. The early response, from Day 7 onwards,
comprises a substantial improvement in time-to-response and
patient convenience, and emphasizes the clinical relevance of the
FCM treatment. Numbers-needed-to-treat (5.9 for 50% fatigue
reduction and 8.0 for $1-point decrease of PFS total score) are
comparable to those for psychological treatments of adult
depression [27].
The strength of these results is supported by the consistent
improvement in all PFS subscores and mental QoL (SF-12). The
Table 2. Primary endpoint – Fatigue (% [n]) (ITT).
FCM (N=144) Placebo (N=146) Difference [95% CI] FCM–placebo on Day 56, P-value
$1 point decrease in total PFS 65.3 (94) 52.7 (77) 12.5 [1.3, 23.8], P = 0.030
PFS Piper fatigue scale.
doi:10.1371/journal.pone.0094217.t002
Table 3. Secondary endpoints – Fatigue, QoL and cognitive function tests (mean [SD]) (ITT).
FCM (N=144) Placebo (N=146)
Baseline Day 56 Baseline Day 56
Difference [95% CI] in changes
from baseline to Day 56, P-value
PFS total score{ 6.46 (1.16) 4.26 (2.08) 6.37 (1.33) 5.01 (2.02) 20.80 [21.26, 20.34], P,0.001
PFS behavioral severity{ 6.45 (1.44) 4.00 (2.33) 6.33 (1.56) 4.77 (2.27) 20.86 [21.36, 20.35], P,0.001
PFS affective meaning{ 7.23 (1.27) 4.71 (2.48) 7.00 (1.53) 5.44 (2.31) 20.89 [21.41, 20.37], P,0.001
PFS sensory{ 6.74 (1.33) 4.60 (2.21) 6.67 (1.56) 5.29 (2.15) 20.72 [21.21, 20.23], P = 0.004
PFS cognitive/mood{ 5.59 (1.41) 3.88 (1.82) 5.63 (1.51) 4.65 (1.87) 20.75 [21.16, 20.34], P,0.001
SF-12 mental health` 41.3 (9.7) 47.3 (8.7) 42.2 (9.2) 45.1 (9.1) 3.0 [0.9, 5.2], P = 0.007
SF-12 physical health` 44.5 (8.2) 49.1 (7.4) 43.9 (8.2) 46.7 (7.7) 1.7 [20.1, 3.6], P = 0.067
VAS alertness` 46.5 (12.7) 60.7 (17.5) 46.9 (13.8) 55.6 (17.1) 5.16 [1.33, 8.98], P = 0.008
VAS contentment` 60.6 (13.9) 69.8 (16.23) 61.2 (14.6) 65.7 (15.3) 4.37 [0.98, 7.76], P = 0.012
VAS calmness` 56.5 (16.1) 66.6 (17.6) 58.7 (16.0) 63.6 (15.1) 3.64 [20.08, 7.35], P = 0.055
CFT power of attention [msec]{ 1146 (127) 1165 (129) 1162 (122) 1190 (136) 211.7 [230.6, 7.3], P = 0.23
CFT continuity of attention` 91.6 (2.6) 91.9 (2.9) 91.2 (4.1) 91.0 (4.8) 0.64 [20.10, 1.39], P = 0.09
CFT quality of working memory` 1.85 (0.22) 1.87 (0.19) 1.86 (0.22) 1.80 (0.35) 0.054 [20.004, 0.113], P = 0.07
CFT quality of episodic memory` 221 (56) 243 (57) 219 (51) 240 (52) 2.65 [27.20, 12.50], P = 0.60
CFT speed of memory [msec]{ 3187 (609) 2944 (502) 3191 (624) 3008 (491) 255.5 [2123.9, 12.8], P = 0.11
{A negative value of the difference FCM–placebo is in favor of FCM;
`A positive value of the difference FCM–placebo is in favor of FCM.
PFS Piper fatigue scale; QoL quality-of-life; SF short form; VAS visual analogue scale (results in mm); CFT cognitive function test (results in msec).
doi:10.1371/journal.pone.0094217.t003
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mental score reached by the FCM group is comparable to the
norm value assessed for 35-year-old women in a general
population (48610 points) [28]. Furthermore, the improvements
in self-rated alertness, contentment and calmness are an addition-
al, independent assessment of patients and support the findings for
PFS and SF-12.
Changes in the cognitive function test subscales did not reach
statistical significance in the overall trial population. However, in
patients with ferritin ,15 mg/L, a significant difference in ‘power
of attention’ was observed in FCM- vs. placebo-treated patients.
The 43 msec improvement in power of attention compares to
differences between cancer patients with ECOG (Eastern Coop-
D
Figure 3. Mean changes (D) in reticulocyte counts, Hb levels, MCV and TSAT (error bars SD). The rapid increase of reticulocyte counts in
the FCM group is in line with early FCM-associated improvement of the fatigue total score (fig. 2B). The significantly higher increase in reticulocyte
counts in the FCM group at Days 7 and 28 (A) translated into higher increases of Hb and MCV at Days 28 and 56 (B,C). The early FCM-associated
increase in reticulocyte counts remained significantly higher compared to placebo when analysing the subgroup of patients with Hb$120 g/L (P,
0.001 for Days 7 and 28). This suggests that iron deficiency without anaemia affected erythropoiesis in these apparently healthy women and raises
doubts whether the currently recommended Hb cut-off level of 120 g/L to diagnose anaemia in premenopausal, menstruating women is appropriate.
TSAT remained significantly improved until the end of the 56-day study period (D). *P,0.0001 for difference between FCM and placebo group in
reticulocyte counts and Hb levels, respectively.
doi:10.1371/journal.pone.0094217.g003
Table 4. Secondary endpoints – Hematologic parameters (% [n] or mean [SD]) (ITT).
FCM (N=144) Placebo (N=146)
Baseline Day 56 Baseline Day 56 Difference [95% CI] FCM–placebo on Day 56, P-value
Hb $120 g/L`,1 86.8 (125) 100 (144) 85.6 (125) 80.8 (118) 19.2 [12.8, 25.6], P,0.001
Serum ferritin $50 mg/L`,1 0.7 (1) 99.3 (143) 1.4 (2) 2.1 (3) 97.3 [94.6, 99.9], P,0.001
TSAT $20%`,1 9.9 (14) 81.3 (117) 13.8 (20) 32.9 (48) 48.4 [38.4, 58.3], P,0.001
MCV (fl) `,1 87.3 (4.5) 89.6 (3.9) 87.4 (4.4) 87.2 (4.8) 2.41 [1.39, 3.42], P,0.0001
`A positive value of the difference FCM–placebo is in favor of FCM;
1Mean Hb levels at Day 56 were 13467.7 g/L (FCM) vs. 127610.1 g/L (placebo), median serum ferritin levels at Day 56 were 169 mg/L (FCM) vs. 16 mg/L (placebo) and
median TSAT was 27% (FCM) vs. 15% (placebo).
Hb hemoglobin; TSAT transferrin saturation; MCV mean corpuscular volume.
doi:10.1371/journal.pone.0094217.t004
Single Dose Ferric Carboxymaltose Improves Fatigue
PLOS ONE | www.plosone.org 7 April 2014 | Volume 9 | Issue 4 | e94217
erative Oncology Group) score zero (fully active) and one (can
work but restricted activity) for whom medical fatigue treatment is
more common [29]. In line with the observed treatment effect in
FCM- vs. placebo-treated patients, the improvement in fatigue
and cognitive function scores correlated with the increase in
ferritin levels. Within the group of FCM-treated patients; however,
the magnitude of changes in ferritin levels did not predict or
correlate with changes in the endpoint scores. Also prior trials did
not show a correlation between changes in serum ferritin and
fatigue improvement [7],[8]. However, recent improvements in
imaging techniques [30] may allow monitoring of the cerebral iron
status and its potential correlation with fatigue in future trials.
Screening failures were not systematically recorded, yet a TSAT
$20% was the main reason. This confirms that not every fatigued
patient is automatically iron-deficient and appropriate iron status
assessment is mandatory before initiating any kind of iron therapy.
The selection of cut-off levels defining iron deficiency anemia
often raises controversies. Despite the WHO’s definition of non-
anemic as Hb$120 g/L, the cut-off for inclusion in this study was
set slightly lower (Hb$115 g/L) in order to include women with a
borderline Hb that might have resulted from physiological
fluctuations in this population (e.g. a transient drop in Hb after
menstruation). The selected cut-off is in line with guidelines for the
management of heavy menstrual bleeding [31] (approved and
endorsed by the Royal New Zealand College of General
Practitioners) and some textbooks [32],[33]. Also one of the prior
studies investigating oral iron in fatigued women used a lower than
the WHO-recommended cut-off ($117 g/L) [7]. The serum
ferritin cut-off is in line with prior studies on iron-based fatigue
treatment [5],[8] but lower compared to conditions associated
with chronic inflammation. A TSAT ,20% is a widely accepted
definition of insufficiently available iron and iron-restricted
erythropoiesis [17],[20].
The PFS response in women with Hb $120 g/L confirmed the
benefit of FCM in fatigue improvement among women that are
non-anemic according to the WHO definition. This is in line with
results in iron-deficient chronic heart failure patients showing
significant improvements in cardiac functional class and physical
performance in FCM- compared to placebo-treated patients
regardless whether they were anemic or non-anaemic [34].
In contrast to the placebo group, all FCM-treated patients
achieved or maintained Hb levels $120 g/L at Day 56. The
transient increase in reticulocyte counts at Days 7 and 28
(statistically significantly better with FCM than placebo in both
the overall trial population and the subgroup with Hb $120 g/L)
together with the decrease in sTfR in FCM-treated patients
indicates that FCM-based iron repletion enhanced erythropoiesis.
Notably, the PREFER study was the first trial investigating the
safety and efficacy of FCM in fatigued but otherwise apparently
healthy subjects. Together with the quite young age of the study
population, this may have led to an overly cautious adverse event
reporting rate also known as nocebo effect and suggested by the
unusually high TEAE rate in the placebo arm. Accordingly, the
frequency of FCM-related TEAEs (28%; all known side effects of
FCM) seems to be higher than in other studies and associated with
patients ,34 years of age [34–37]. The binary causality
assessment (related/unrelated) together with the single-blinded
design may have added to over-reporting of related events
compared to studies using the four-graded WHO causality scale
[38] or double-blinding [35],[36]. Since the proportions of
patients with at least one TEAE were not significantly different
between those with a body weight below or above 65 kg, FCM
doses of 1000 mg iron (max. 20 mg/kg) should be considered for
iron-deficient patients who may benefit from i.v. iron treatment.
Patients with a body weight below 65 kg who might be concerned
about a potential risk of treatment-related symptoms, may be
scheduled for two administrations of 500 mg iron with a one-week
interval.
In contrast to the controversial discussion about a potential
impact of i.v. iron on immune function [39], no difference in the
frequency of infections was observed between the FCM and the
placebo group. Similar to observations in earlier studies
Table 5. Adverse events profile (SAF).
FCM (N=145) % (n), events Placebo (N=149) % (n), events P-value*
Any TEAE (total) 57.2% (83), 209 49.0% (73), 114 n.s.
– related{ 28.3% (41), 111 3.4% (5), 6 P,0.0001
Any mild or moderate TEAE 53.8% (78), 198 49.0% (73), 114 n.s.
– related{ 25.5% (37), 101 3.4% (5), 6 P,0.0001
Any severe TEAE 3.4% (5), 11 0 P = 0.03*
– related{ 2.8% (4), 10 0 P = 0.06*
Any SAE 0.7% (1), 1 0 n.s.
– related{ 0 0 n.s.
Most common TEAEs (in $5% of patients):
– Headache 15.9% (23), 30 10.7% (16), 18 n.s.
– Nasopharyngitis 9.0% (13), 13 5.4% (8), 8 n.s.
– Pyrexia 8.3% (12), 13 1.3% (2), 2 p = 0.005
– Nausea 5.5% (8), 11 1.3% (2), 2 p = 0.06*
*p-values calculated by x2-test except for severe TEAEs and nausea (Fisher’s exact test);
{TEAEs with a temporal relationship to the study drug administration if no other drug, therapeutic intervention or underlying condition provides a sufficient explanation
for the observed event.
Three mild cases of urticaria that were considered FCM-related resolved without medication. Among the five patients that experienced one or more severe TEAEs, one
patient had nausea, heavy legs, headache, arthralgia and myalgia, one patient had hematoma and two times discoloration at injection sites, and three patients had one
severe TEAE each (headache, cough and night sweat, respectively).
TEAE treatment emergent adverse event; SAE serious adverse event; n.s. not significant.
doi:10.1371/journal.pone.0094217.t005
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[36],[37],[40–42], the transient decrease in serum phosphate levels
was asymptomatic and did not require treatment. The observation
of only one moderate and spontaneously resolving hypersensitivity
reaction is in line with prior experience that the dextran-free
compound FCM exerts only a very low risk of hypersensitivity
reactions [43]. Also a recent review of the risk of allergic reactions
by the European Medicines Agency (EMA) concluded that the
benefits of i.v. iron outweigh the risks in the treatment of ID.
Accordingly, no test dose is needed although availability of
resuscitation facilities is still required [44].
Since controlled studies of FCM in different patient populations
confirmed a positive benefit/risk ratio for treatment with a single
FCM dose of 1000 mg iron [34],[37],[45], and a prior pilot study
in a similar population suggested a beneficial effect of iron sucrose
given at a total dose of 800 mg iron, the approved FCM treatment
with 1000 mg as a single dose was selected for this study.
Although ID is the major cause of fatigue, a substantial placebo-
effect has been observed in this and other studies [5]. This may be
associated with the emotional component of fatigue and the i.v.
administration route. Notably, placebo-treated patients showed
only modest fatigue reduction after the initial decrease, whereas
the mean PFS of FCM-treated patients continuously decreased
until Day 56 after the rapid initial reduction. Substantial placebo
effects have also been reported in prior fatigue studies [5],[7] as
well as for the management of another patient-reported outcome
such as chronic low back pain [46]. The impact of patient
expectations, associative learning and cognitive factors on the
placebo response across different diseases and physiological
systems which may trigger even complex neurobiological phe-
nomena has been described before [47].
In clinical practice, active women may prefer i.v. iron due to its
rapid effect, few adverse events and the single administration
compared with up to three times daily oral medication. Although
the single FCM administration can effectively replenish iron stores,
the iron status (i.e. ferritin levels and % TSAT) should reassessed
after a certain period (e.g. three months) to evaluate whether re-
treatment is necessary. Since i.v. administration requires medical
expertise it may be more expensive than oral iron treatment.
While economic studies have shown that FCM may reduce the
costs of ID treatment compared to other i.v. iron preparations
[37],[48], a similar cost analysis vs. oral iron has not yet been
performed.
Conclusions
The results of this placebo-controlled study show the effective-
ness of a single ferric carboxymaltose dose to rapidly reduce
fatigue and to improve cognitive function scores in iron-deficient
women with normal to borderline Hb. All FCM-treated patients
achieved or maintained a normal Hb level. As with most placebo-
controlled studies, more side effects were reported with the active
study treatment. Although oral iron will remain the common
treatment of iron deficiency in practice, the results of this study
confirm that i.v. ferric carboxymaltose can serve as an effective
alternative if oral iron is not tolerated or cannot be used. Overall,
the results favor the maintenance of a normal iron status
independent of Hb levels. The assessment and treatment of ID
in women with unexplained fatigue should prevent incorrect
diagnosis and might reduce inappropriate medication use.
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